Clinical trial · Interventional
Strength Training on Pancreatic Cancer
NCT01395563CI-TRIAL-00017134STOPCwithdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether prednisone, methotrexate, and cyclophosphamide are effective in the treatment of rapidly progressive hearing loss in both ears due to autoimmune inner ear disease (AIED).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cachexia | — | UNRESOLVED | — |
| Myopathy | — | UNRESOLVED | — |
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| strength training | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- pancreatic cancer patients
- interventionNames
- Behavioral: strength training
- type
- EXPERIMENTAL
- label
- 2
- description
- pancreatic cancer patients
- interventionNames
- Behavioral: strength training
Primary outcomes (1)
- measure
- muscle mass and strength
- timeFrame
- after 8 weeks of intervention
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * patients with pancreatic carcinomas after surgery (resection or exploration) * given consent Exclusion Criteria: * acute infection * pain * no mobility or ability for walking or standing * severe neurological disorders (apoplex, morbus Parkinson, paresis of the lower extremeties) * severe cardiac or cardiovascular diseases (z.B. heart insufficiency NYHA III, myocardial infarction \<3 months) * rhytmical disorders, that contraindicate ergospirometric examinations * cardiac therapy with digitalis pharmacy * unclear syncopes * severe pulmonal insufficiency * renal insufficiency (GFR \< 30% at Krea \>3 mg/dl) * synchronous participation in an other clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.